Published in Nat Rev Microbiol on January 01, 2009
The evolution of drug resistance and the curious orthodoxy of aggressive chemotherapy. Proc Natl Acad Sci U S A (2011) 2.25
The past and future of tuberculosis research. PLoS Pathog (2009) 1.94
Identifying multidrug resistant tuberculosis transmission hotspots using routinely collected data. Tuberculosis (Edinb) (2012) 1.63
Therapeutic immunization against Mycobacterium tuberculosis is an effective adjunct to antibiotic treatment. J Infect Dis (2012) 1.62
Myths and misconceptions: the origin and evolution of Mycobacterium tuberculosis. Nat Rev Microbiol (2009) 1.58
CD1-restricted adaptive immune responses to Mycobacteria in human group 1 CD1 transgenic mice. J Exp Med (2009) 1.43
Genotyping of Mycobacterium tuberculosis: application in epidemiologic studies. Future Microbiol (2011) 1.39
Epidemiology and challenges to the elimination of global tuberculosis. Clin Infect Dis (2010) 1.36
Monitoring therapeutic efficacy by real-time detection of Mycobacterium tuberculosis mRNA in sputum. Clin Chem (2009) 1.21
Assessing spatiotemporal patterns of multidrug-resistant and drug-sensitive tuberculosis in a South American setting. Epidemiol Infect (2010) 1.13
Development of new vaccines and drugs for TB: limitations and potential strategic errors. Future Microbiol (2011) 1.10
Increased Foxp3 expression in guinea pigs infected with W-Beijing strains of M. tuberculosis. Tuberculosis (Edinb) (2011) 1.09
Spontaneous emergence of multiple drug resistance in tuberculosis before and during therapy. PLoS One (2011) 1.09
The role of B cells and humoral immunity in Mycobacterium tuberculosis infection. Adv Exp Med Biol (2013) 1.09
A mycolic acid-specific CD1-restricted T cell population contributes to acute and memory immune responses in human tuberculosis infection. J Clin Invest (2011) 1.07
Multiple introductions of multidrug-resistant tuberculosis into households, Lima, Peru. Emerg Infect Dis (2011) 1.07
Activities of TMC207, rifampin, and pyrazinamide against Mycobacterium tuberculosis infection in guinea pigs. Antimicrob Agents Chemother (2010) 1.05
On the spread and control of MDR-TB epidemics: an examination of trends in anti-tuberculosis drug resistance surveillance data. Drug Resist Updat (2014) 1.00
Nanobead-based interventions for the treatment and prevention of tuberculosis. Nat Rev Microbiol (2010) 0.99
Tuberculosis chemotherapy in the 21 century: Back to the basics. Lung India (2011) 0.97
Rates and risk factors for drug resistance tuberculosis in Northeastern China. BMC Public Health (2013) 0.96
Strategies to minimize antibiotic resistance. Int J Environ Res Public Health (2013) 0.96
Modelling the performance of isoniazid preventive therapy for reducing tuberculosis in HIV endemic settings: the effects of network structure. J R Soc Interface (2011) 0.94
Evolutionary consequences of drug resistance: shared principles across diverse targets and organisms. Nat Rev Genet (2015) 0.93
Crystal structure of bovine CD1b3 with endogenously bound ligands. J Immunol (2010) 0.92
Pathways to multidrug-resistant tuberculosis diagnosis and treatment initiation: a qualitative comparison of patients' experiences in the era of rapid molecular diagnostic tests. BMC Health Serv Res (2015) 0.92
Determinants of multidrug-resistant tuberculosis clusters, California, USA, 2004-2007. Emerg Infect Dis (2010) 0.91
Mycobacterium tuberculosis Rv2419c, the missing glucosyl-3-phosphoglycerate phosphatase for the second step in methylglucose lipopolysaccharide biosynthesis. Sci Rep (2011) 0.89
Biochemical characterization of the maltokinase from Mycobacterium bovis BCG. BMC Biochem (2010) 0.89
Bacterial carbonic anhydrases as drug targets: toward novel antibiotics? Front Pharmacol (2011) 0.88
Extensive drug resistance in malaria and tuberculosis. Emerg Infect Dis (2010) 0.86
Molecular and phenotypic characterization of multidrug-resistant Mycobacterium tuberculosis isolates resistant to kanamycin, amikacin, and capreomycin in China. Eur J Clin Microbiol Infect Dis (2014) 0.82
Tuberculosis vaccine types and timings. Clin Vaccine Immunol (2014) 0.81
National and international policies to mitigate disease threats. Philos Trans R Soc Lond B Biol Sci (2012) 0.80
Therapeutic vaccination against relevant high virulence clinical isolates of Mycobacterium tuberculosis. Tuberculosis (Edinb) (2013) 0.78
Incidence and Geographic Distribution of Extensively Drug-Resistant Tuberculosis in KwaZulu-Natal Province, South Africa. PLoS One (2015) 0.77
Genetic features of Mycobacterium tuberculosis modern Beijing sublineage. Emerg Microbes Infect (2016) 0.76
The within-host population dynamics of Mycobacterium tuberculosis vary with treatment efficacy. Genome Biol (2017) 0.75
Extracts of six Rubiaceae species combined with rifampicin have good in vitro synergistic antimycobacterial activity and good anti-inflammatory and antioxidant activities. BMC Complement Altern Med (2016) 0.75
Translating basic science insight into public health action for multidrug- and extensively drug-resistant tuberculosis. Respirology (2012) 0.75
Molecular detection of multidrug-resistant tuberculosis among smear-positive pulmonary tuberculosis patients in Jigjiga town, Ethiopia. Infect Drug Resist (2017) 0.75
Legionella pneumophila Carbonic Anhydrases: Underexplored Antibacterial Drug Targets. Pathogens (2016) 0.75
In vitro evaluation of tetrazoles as a novel class of Antimycobacterium tuberculosis agents. Adv Pharm Bull (2012) 0.75
SInCRe-structural interactome computational resource for Mycobacterium tuberculosis. Database (Oxford) (2015) 0.75
The yield of screening symptomatic contacts of multidrug-resistant tuberculosis cases at a tertiary hospital in Addis Ababa, Ethiopia. BMC Res Notes (2015) 0.75
Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet (2006) 21.60
Antibacterial resistance worldwide: causes, challenges and responses. Nat Med (2004) 10.46
Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. JAMA (2000) 8.42
Prospects for worldwide tuberculosis control under the WHO DOTS strategy. Directly observed short-course therapy. Lancet (1998) 6.94
Worldwide emergence of extensively drug-resistant tuberculosis. Emerg Infect Dis (2007) 6.41
Comprehensive treatment of extensively drug-resistant tuberculosis. N Engl J Med (2008) 6.17
WHO's new Stop TB Strategy. Lancet (2006) 5.59
Global incidence of multidrug-resistant tuberculosis. J Infect Dis (2006) 5.42
The competitive cost of antibiotic resistance in Mycobacterium tuberculosis. Science (2006) 5.41
The effect of tuberculosis control in China. Lancet (2004) 4.84
A marked difference in pathogenesis and immune response induced by different Mycobacterium tuberculosis genotypes. Clin Exp Immunol (2003) 4.66
XDR-TB in South Africa: no time for denial or complacency. PLoS Med (2007) 4.20
Treatment of extensively drug-resistant tuberculosis in Tomsk, Russia: a retrospective cohort study. Lancet (2008) 4.17
Beijing/W genotype Mycobacterium tuberculosis and drug resistance. Emerg Infect Dis (2006) 3.93
Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study. Lancet (2005) 3.81
The influence of host and bacterial genotype on the development of disseminated disease with Mycobacterium tuberculosis. PLoS Pathog (2008) 3.79
Evolution of the extensively drug-resistant F15/LAM4/KZN strain of Mycobacterium tuberculosis in KwaZulu-Natal, South Africa. Clin Infect Dis (2007) 3.74
Multidrug-resistant tuberculosis management in resource-limited settings. Emerg Infect Dis (2006) 3.32
Influence of multidrug resistance on tuberculosis treatment outcomes with standardized regimens. Am J Respir Crit Care Med (2008) 3.04
Interventions to reduce tuberculosis mortality and transmission in low- and middle-income countries. Bull World Health Organ (2002) 3.03
Does DOTS work in populations with drug-resistant tuberculosis? Lancet (2005) 2.95
Modeling epidemics of multidrug-resistant M. tuberculosis of heterogeneous fitness. Nat Med (2004) 2.83
Tuberculosis infection control in resource-limited settings in the era of expanding HIV care and treatment. J Infect Dis (2007) 2.79
Population genetics study of isoniazid resistance mutations and evolution of multidrug-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother (2006) 2.69
Erasing the world's slow stain: strategies to beat multidrug-resistant tuberculosis. Science (2002) 2.65
Effect of rpoB mutations conferring rifampin resistance on fitness of Mycobacterium tuberculosis. Antimicrob Agents Chemother (2004) 2.53
Criteria for the control of drug-resistant tuberculosis. Proc Natl Acad Sci U S A (2000) 2.46
Lack of development of new antimicrobial drugs: a potential serious threat to public health. Lancet Infect Dis (2005) 2.41
Challenges in estimating the total burden of drug-resistant tuberculosis. Am J Respir Crit Care Med (2008) 2.33
Worldwide incidence of multidrug-resistant tuberculosis. J Infect Dis (2002) 2.33
Predicting antibiotic resistance. Nat Rev Microbiol (2007) 2.28
The dynamics of tuberculosis in response to 10 years of intensive control effort in Peru. J Infect Dis (2001) 2.23
Modeling the emergence of the 'hot zones': tuberculosis and the amplification dynamics of drug resistance. Nat Med (2004) 2.20
The effect of drug resistance on the fitness of Mycobacterium tuberculosis. Lancet Infect Dis (2003) 2.17
Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis. Clin Infect Dis (2008) 2.17
XDR-TB: entering the post-antibiotic era? Int J Tuberc Lung Dis (2006) 1.86
Long term efficacy of DOTS regimens for tuberculosis: systematic review. BMJ (2008) 1.85
Will tuberculosis become resistant to all antibiotics? Proc Biol Sci (2001) 1.79
The Beijing genotype and drug resistant tuberculosis in the Aral Sea region of Central Asia. Respir Res (2005) 1.79
New tuberculosis therapeutics: a growing pipeline. J Infect Dis (2007) 1.78
Risk of acquired drug resistance during short-course directly observed treatment of tuberculosis in an area with high levels of drug resistance. Clin Infect Dis (2007) 1.76
Medicine. A portfolio model of drug development for tuberculosis. Science (2006) 1.75
Tuberculosis recurrence and mortality after successful treatment: impact of drug resistance. PLoS Med (2006) 1.69
Underreported threat of multidrug-resistant tuberculosis in Africa. Emerg Infect Dis (2008) 1.56
Contribution of horizontally acquired genomic islands to the evolution of the tubercle bacilli. Mol Biol Evol (2007) 1.47
Spread of a low-fitness drug-resistant Mycobacterium tuberculosis strain in a setting of high human immunodeficiency virus prevalence. J Clin Microbiol (2008) 1.46
Horizontal transfer of a virulence operon to the ancestor of Mycobacterium tuberculosis. Mol Biol Evol (2006) 1.46
Impact of drug resistance on fitness of Mycobacterium tuberculosis strains of the W-Beijing genotype. FEMS Immunol Med Microbiol (2004) 1.36
Management of extensively drug-resistant tuberculosis in Peru: cure is possible. PLoS One (2008) 1.34
Beijing and Haarlem genotypes are overrepresented among children with drug-resistant tuberculosis in the Western Cape Province of South Africa. J Clin Microbiol (2006) 1.28
Scaling up programmatic management of drug-resistant tuberculosis: a prioritized research agenda. PLoS Med (2008) 1.15
Distribution of rpoB mutations among multidrug-resistant Mycobacterium tuberculosis (MDRTB) strains from Thailand and development of a rapid method for mutation detection. Clin Microbiol Infect (2008) 1.11
IS6110, a Mycobacterium tuberculosis complex-specific insertion sequence, is also present in the genome of Mycobacterium smegmatis, suggestive of lateral gene transfer among mycobacterial species. J Bacteriol (2008) 1.10
Can DOTS control multidrug-resistant tuberculosis? Lancet (2005) 1.09
Treatment outcomes in extensively resistant tuberculosis. N Engl J Med (2008) 1.08
Design issues in pivotal drug trials for drug sensitive tuberculosis (TB). Tuberculosis (Edinb) (2008) 1.08
Drug-resistant tuberculosis. In South Africa, XDR TB and HIV prove a deadly combination. Science (2008) 1.08
The decline of tuberculosis epidemics under chemotherapy: a case study in Morocco. Int J Tuberc Lung Dis (2007) 1.04
Age-period-cohort analysis of tuberculosis notifications in Hong Kong from 1961 to 2005. Thorax (2007) 1.03
Genotype and phenotype relationships and transmission analysis of drug-resistant tuberculosis in Singapore. Int J Tuberc Lung Dis (2007) 0.98
Epidemiology and treatment of multidrug resistant tuberculosis. Semin Respir Crit Care Med (2008) 0.96
Predicting the future of XDR tuberculosis. Lancet Infect Dis (2007) 0.95
The clinical management of drug-resistant tuberculosis. Curr Opin Pulm Med (2007) 0.93
Extensively drug-resistant tuberculosis in sub-Saharan Africa: an emerging public-health concern. Trans R Soc Trop Med Hyg (2008) 0.84
Long-term follow-up for multidrug-resistant tuberculosis. Emerg Infect Dis (2006) 0.83
Environmental infection control of tuberculosis. Semin Respir Infect (2003) 0.83